Learning from Failure

Cardiovascular toxicity often hinders success – are companies picking the wrong compounds?

Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.)

When it comes to drug safety failure, toxicity – especially to the cardiovascular system – is a major stumbling block. In an effort to learn from past failures and help improve success rates, ApconiX and PhysioStim have teamed up to create a European Center of Excellence for Preclinical Cardiovascular Safety Evaluation. The companies hope to provide high-throughput screening to help pharma companies decide whether their compound is on the right track to pass safety tests. Here, we speak with a spokesperson from ApconiX to learn more.

Read more here: Learning from Failure


By |2018-07-11T15:26:46+00:00November 2nd, 2017|Ion Channels, Press|Comments Off on Learning from Failure

About the Author:

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.